作者
Lorenz Lehmann,Markus Heckmann,Guillaume Bailly,Daniel Finke,Adrien Procureur,John R. Power,Frederic Stein,Marie Bretagne,Stéphane Éderhy,Charlotte Fenioux,Omar Hamwy,Elisa Funck‐Brentano,Emanuela Romano,Laurence Piéroni,Jan P. Münster,Yves Allenbach,C. Anquetil,Sarah Léonard-Louis,Nicolas L. Palaskas,Salim S. Hayek,Hugo A. Katus,Evangelos Giannitsis,Norbert Frey,Ziya Kaya,Javid J. Moslehi,Edi Prifti,Joe‐Elie Salem,Franck Thuny,Shanthini M. Crusz,Aarti Asnani,Anja Karlstaedt,Fanny Rocher,Elise Paven,Michel Obéid,Wei Ting Chan,Danette Flint,Dimitri Arangalage,Pierre‐Yves Courand,Martin Nicol,Eve Cariou,Yuichi Tamura,Roberta Florido,Sanjeev Francis,Darryl Leong,Nicolas Piriou,Nausheen Akhter,Sandhu Shahneen,Osnat Itzhaki Ben Zadok,Manhal Habib,Pankit Vachhani,Giovanni Peretto,Han Zhu,Michal Laufer Perl,Mandar A. Aras,Joachim Alexandre,Carrie Lenneman,Joshua Levenson,Anita Deswal,Vlad G. Zaha,Elizabeth M. Gaughan,Steven M. Ewer,Douglas B. Johnson,Lauren A. Baldassarre
摘要
Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established.